Regeneron to Acquire 23andMe for $256M
Regeneron Pharmaceuticals has agreed to acquire 23andMe’s consumer genetics business and assets for $256 million, following 23andMe’s Chapter 11 bankruptcy.
More Videos
From SpaceX to Hollywood: The Deals Reshaping 2026
Dena Jalbert, founder and CEO of Align Business Advisory Services, breaks down 2026’s M&A surge, SpaceX IPO buzz, and major media shakeups.
Chocolate Hangover: Why Prices Are Staying High After Valentine’s Day & Easter
David Branch of Wells Fargo explains why cocoa prices are falling but some candy costs remain high and when consumers may finally see relief at checkout.
Understanding Artemis II: Humanity’s Next Giant Leap Toward the Moon
Colonel Chris Hadfield, astronaut and best-selling author, breaks down Artemis II and why NASA’s next crewed mission is key to returning humans to the Moon.
Why This War Could Change Oil Forever
Ben Geman, Energy Reporter at Axios, explains how the Iran war could reshape global energy—disrupting supply, shifting power, and accelerating a new regime.
War, Trade, and Rates: What’s Moving Markets Now
Max Gokhman, Deputy Chief Investment Officer of Franklin Templeton, breaks down how geopolitics is shaping markets and what it means for investors.
America’s Offices Sit Empty Despite RTO Mandates
Emily Peck, National Correspondent at Axios, explains why office vacancies hit 21% despite RTO pushes, highlighting a lasting shift in how Americans work.
